To assess the effects of PPARγ ligand therapy on breast cancer, we conducted apilot study of short-term administration of rosiglitazone (4 mg taken twice aday) to women newly diagnosed with early stage breast cancer (Stages 0 to II) during the two- to six-week period between diagnostic biopsy and surgical removal of the cancer [69]. Here, PPARG is linked to breast carcinoma.